Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
Stephen D. Wiviott(Brigham and Women's Hospital), Elliott M. Antman(Brigham and Women's Hospital), Drew A. Purdy(St. Michael's Hospital), Dominick J. Angiolillo(Jacksonville University), Shaun G. Goodman(St. Michael's Hospital), Freek W.A. Verheugt(Radboud University Nijmegen), Sabina A. Murphy(Brigham and Women's Hospital), Carolyn H. McCabe(Brigham and Women's Hospital), Ramón Corbalán(St. Michael's Hospital), Simcha Meisel(St. Michael's Hospital), Anthony J. Dalby(Milpark Hospital), Eugene Braunwald(Brigham and Women's Hospital)
Cited by 757
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.1k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k